An NKT-mediated autologous vaccine generates CD4 T-cell–dependent potent antilymphoma immunity
- 15 September 2007
- journal article
- Published by American Society of Hematology in Blood
- Vol. 110 (6) , 2013-2019
- https://doi.org/10.1182/blood-2006-12-061309
Abstract
Relapses occurring in most patients with lymphoma after antibody or chemotherapy highlight a need for effective vaccination approaches. Autologous tumors are ideal sources of patient-specific tumor antigens for vaccines; however, their poor immunogenicity has been a major obstacle in practice. Natural killer T (NKT) cells have recently emerged as crucial regulators of autoimmunity and tumor immunosurveillance. Here, we show that an autologous lymphoma vaccine that activates NKT cells generated tumor-specific protective immunity in experimental mice. Single vaccination with alpha-galactosylceramide (alphaGC)-loaded A20 lymphoma cells elicited effective antitumor immunity against tumor challenge. This vaccination strategy also induced significant tumor regression in A20-bearing mice. Importantly, the survivors from primary tumor inoculation were all resistant to tumor rechallenge, indicative of established adaptive memory immunity. Depletion as well as adoptive transfer studies revealed an exclusive role of conventional CD4(+) but not CD8(+) T cells in mediating antitumor immunity. In addition, we found normal hematopoietic compartments in the vaccinated mice. Therefore, NKT ligand-loaded lymphoma elicits long-lasting and effective antitumor immunity, which can be further developed as patient- and tumor-specific immunotherapy against human lymphomas.Keywords
This publication has 34 references indexed in Scilit:
- In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunityBlood, 2006
- A nonclassical non-Vα14Jα18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillanceThe Journal of Experimental Medicine, 2005
- Immunogenicity, Including Vitiligo, and Feasibility of Vaccination With AutologousGM-CSF–Transduced Tumor Cells in Metastatic Melanoma PatientsJournal of Clinical Oncology, 2005
- Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cellsThe Journal of Experimental Medicine, 2005
- Potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): enhanced immunogenicity of CLL cells via infection with vectors encoding for multiple costimulatory moleculesBlood, 2005
- Differential antitumor immunity mediated by NKT cell subsets in vivoThe Journal of Experimental Medicine, 2005
- Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosyl-ceramide loaded mature dendritic cells in cancer patientsThe Journal of Experimental Medicine, 2005
- Primary Antitumor Immune Response Mediated by CD4+ T CellsImmunity, 2005
- NKT cell ligand α‐galactosylceramide blocks the induction of oral tolerance by triggering dendritic cell maturationEuropean Journal of Immunology, 2004
- CD1d is expressed on B‐chronic lymphocytic leukemia cells and mediates α‐galactosylceramide presentation to natural killer T lymphocytesInternational Journal of Cancer, 2004